The Shenzhen Institute of Advanced Technology has recognized its researcher for his pioneering work in synthetic biology
SANTA CLARA, Calif., April 3, 2023.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) announced today Dr. Chenli Liu He was selected to receive the Thought Leader Award. The evaluation will help pioneer studies in synthetic biology, specifically research to develop a synthetic cell that combines the properties of individual cells using a fundamental approach to understanding biological groups.
Liu is the president of the Dr Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences in China He is also an author iSynBio at SIAT, the largest research institute focused on synthetic biology, as well as the chief scientist of the Shenzhen Synthetic Biology Infrastructure.
Dr. Liu’s lab at iSynBio is dedicated to quantitative synthetic biology research. The research is based on the idea of ”quantitative analysis and synthetic reconstruction”, in the basic principles of the formation process of complex biological systems, as well as the rational design principles of synthetic biological systems and other important scientific issues.
Led by Dr. Liu, Shenzhen’s synthetic biology research team has been adhering to the frontiers of science and technology of the world and the country’s greatest needs. They actively participate in major original innovations, original technical sources, and core technology breakthroughs, while promoting the technical level in the field of synthetic biology and the continuous development of new capabilities. Dr. Liu and his team focus on addressing the shortcomings of basic research in synthetic biology, overcoming inherent challenges in the R&D process, and constantly expanding the mainstream economic process of “fundamental research + technological breakthroughs + industrialization achievements + science and technology economics.”1
“I feel privileged to receive this Agilent Thought Leader Award. Synthetic biology is one of the leading interdisciplinary fields of science and technology in the world. A series of disruptive technologies generated from this field will likely lead to a technological revolution in biomedicine, food. and sustainability in the future,” said Dr. Liu. “We will continue to explore and try to build Shenzhen in the global field of synthetic biology technology. I am confident that with Agilent’s support and its world-leading experiments and technology and solutions, our studies in synthetic biology, one of the most cutting-edge fields in the life of science, will soon bear fruit which will provide great benefits”.
“Synthetic biology is an exciting field of research, and its scientific discoveries bring outstanding value to all people,” said Ting Yang, president of Agilent, and general manager of the Greater China Commercial Organization. “Agent is proud to support Dr. Liu with a comprehensive solution that includes Agilent’s portfolio, be it genetic research solutions, cell analysis solutions, chromatography and mass spectrometry solutions, and more, to facilitate the research goal of eco-setting the innovation system of synthetic biology study in China.
“The progress of synthetic biology led to the third biotechnological revolution, from the discovery of the helical structure of DNA, and this new technology is expected to make a stronger impact on how products can be more sustainable,” said Darlene Solomon, senior Agilent. president and chief technology officer. “Agilent has been focused on the field of synthetic biology for many years, and by supporting early researchers like Dr. Liu, it understands our role in accelerating this important development.”
The Agilent Thought Leader Award program promotes fundamental scientific advances by supporting the research, products and expertise of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. To learn more, visit Award Thought Leader Award website
About agile technology
Agile Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemicals markets, delivering insight and innovation that helps our customers bring great science to life. Our full range of agile solutions includes tools, software, services and expertise that provide reliable answers to our clients’ most challenging problems. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agents is available at www.agilent.com. To receive the latest Agilent news, please subscribe to Agilent Newsroom. Follow the Agents in LinkedIn and Facebook.
1 http://www.isynbio.org.cn/institution-jg_en.aspx
View source version on businesswire.com: https://www.businesswire.com/news/home/20230403005364/en/
contact
Noemi Goumillout
Agent Technologies, Inc.
+1 781 266 2819
naomi.goumillout@agilent.com
kirna liu
Acting Technologies, China
+86 10 6439 7889
kirna.liu@agilent.com
